Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype

Oncotarget

Volumn 8, Issue 29, 2017, Pages 47454-47473

  Liang, Yuh Jin ^a   Wang, Chen Yu ^b   Wang, I An ^a   Chen, Yi Wen ^a   Li, Li Tzu ^a   Lin, Chuang Yu ^a   Ho, Ming Yi ^a   Chou, Tsung Lung ^a   Wang, Ya Hui ^a   Chiou, Shih Pin ^a   Lin, Yu Ju ^a   Yu, John ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

Breast cancer stem cell; Ganglioside; GD3 synthase; Glycosphingolipid; Glycosyltransferase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GEFITINIB; PROTEIN GD3S; SYNTHETASE; UNCLASSIFIED DRUG; ALDH1A1 PROTEIN, HUMAN; ALDH1A1 PROTEIN, MOUSE; ALPHA-N-ACETYLNEURAMINATE ALPHA-2,8-SIALYLTRANSFERASE; BIOLOGICAL MARKER; GLYCOSPHINGOLIPID; GROWTH FACTOR RECEPTOR; ISOENZYME; QUINAZOLINE DERIVATIVE; RETINAL DEHYDROGENASE; SIALYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CELL ADHESION; CELL MOTION; CLONAL EVOLUTION; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETICS; HUMAN; METABOLISM; PHENOTYPE; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE 1 FAMILY; ANIMALS; BIOMARKERS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CLONAL EVOLUTION; DISEASE MODELS, ANIMAL; ERBB RECEPTORS; FEMALE; GEFITINIB; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLYCOSPHINGOLIPIDS; HUMANS; ISOENZYMES; MICE; NEOPLASTIC STEM CELLS; PHENOTYPE; QUINAZOLINES; RECEPTORS, GROWTH FACTOR; RETINAL DEHYDROGENASE; SIALYLTRANSFERASES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85024405486     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17665     Document Type: Article

References (42)

1. IUPAC-IUB joint commission on biochemical nomenclature (JCBN) nomenclature of glycolipids recommendations 1997 J Mol Biol. 1999; 286:963-970
2. Hakomori SI. Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett. 2010; 584:1901-1906
3. Prinetti A, Loberto N, Chigorno V, Sonnino S. Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta. 2009; 1788:184-193
4. Miljan EA, Bremer EG. Regulation of growth factor receptors by gangliosides. Sci STKE. 2002; 2002:1-10
5. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumorassociated gangliosides in cancer progression. Biochimie. 2003; 85:455-463
6. Yu RK, Nakatani Y, Yanagisawa M. The role of glycosphingolipid metabolism in the developing brain. J Lipid Res. 2009; 50:S440-445
7. Yamashiro S, Okada M, Haraguchi M, Furukawa K, Lloyd KO, Shiku H. Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj J. 1995; 12:894-900
8. Nishio M, Furukawa K. Incorporation, remodeling and reexpression of exogenous gangliosides in human cancer cell lines in vitro and in vivo. Nagoya J Med Sci. 2004; 67:35-44
9. Groux-Degroote S, Guerardel Y, Julien S, Delannoy P. Gangliosides in breast cancer: new perspectives. Biochemistry (Mosc). 2015; 80:808-819
10. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008; 112:41-52
11. Ruckhaberle E, Karn T, Rody A, Hanker L, Gatje R, Metzler D, Holtrich U, Kaufmann M. Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol. 2009; 135:1005-1013
12. Wang J, Yu RK. Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc Natl Acad Sci U S A. 2013; 110:19137-19142
13. Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, Ohmi Y, Yamauchi Y, Furukawa K. Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem. 2010; 285:27213-27223
14. Hamamura K, Tsuji M, Hotta H, Ohkawa Y, Takahashi M, Shibuya H, Nakashima H, Yamauchi Y, Hashimoto N, Hattori H, Ueda M, Furukawa K. Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem. 2011; 286:18526-18537
15. Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X, Delannoy P. GD synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res. 2010; 8:1526-1535
16. Cazet A, Bobowski M, Rombouts Y, Lefebvre J, Steenackers A, Popa I, Guerardel Y, Le Bourhis X, Tulasne D, Delannoy P. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology. 2012; 22:806-816
17. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012; 122:2066-2078
18. Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori S. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A. 2013; 110:4968-4973
19. Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Pena EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2015; 34:2958-2967
20. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009; 18:17-25
21. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9:265-273
22. Arnold KM, Opdenaker LM, Flynn D, Sims-Mourtada J. Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis. 2015; 8:1-13
23. Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One. 2014; 9:e92444
24. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem. 2005; 280:29828-29836
25. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004; 22:785-794
26. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005; 23:5323-5333
27. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747-752
28. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27:1160-1167
29. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006; 25:2273-2284
30. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009; 4:e6146
31. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011; 5:5-23
32. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010; 32:35-48
33. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12:R68
34. Regina Todeschini A, Hakomori S. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta. 2008; 1780:421-433
35. Steenackers A, Vanbeselaere J, Cazet A, Bobowski M, Rombouts Y, Colomb F, Le Bourhis X, Guerardel Y, Delannoy P. Accumulation of unusual gangliosides G(Q3) and G(P3) in breast cancer cells expressing the G(D3) synthase. Molecules. 2012; 17:9559-9572
36. Lingwood CA. Glycosphingolipid functions. Cold Spring Harb Perspect Biol. 2011; 3
37. Julien S, Bobowski M, Steenackers A, Le Bourhis X, Delannoy P. How do gangliosides regulate RTKs signaling? Cells. 2013; 2:751-767
38. Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 2012; 103:1656-1664
39. Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W, Wang A, Seong YS, Bae I. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med. 2013; 17:648-656
40. Furukawa K, Kambe M, Miyata M, Ohkawa Y, Tajima O, Furukawa K. Ganglioside GD3 induces convergence and synergism of adhesion and hepatocyte growth factor/Met signals in melanomas. Cancer Sci. 2014; 105:52-63
41. Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L, Frattini M. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol. 2012; 27:785-792
42. She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, et al. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer. 2016; 16:587